As filed with the Securities and Exchange Commission on July 23, 2024

Commission File No. 333-280300

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

POST EFFECTIVE AMENDMENT NO. 1

FORM S-8

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

OptimizeRx Corporation
(Exact name of registrant as specified in its charter)
Nevada		26-1265381
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
260 Charles Street, Suite 302, Waltham, MA		02453
(Address of Principal Executive Offices)		(Zip Code)
OptimizeRx Corporation 2021 Equity Incentive Plan
(Full title of the plan)
Marion Odence-Ford, Esquire General Counsel OptimizeRx Corporation 260 Charles Street Suite 302 Waltham, MA 02453 (248) 651-6568
(Name and address of agent for service)
(Telephone number, including area code, of agent for service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 

 

Explanatory Note

 

OptimizeRx Corporation (the “Company”) hereby amends its original Registration Statement on Form S-8 (File No. 333-280300) filed with the Securities and Exchange Commission (the “Commission”) on June 18, 2024 (the “Original Filing”) solely for the purpose of updating the exhibit index to include Exhibit 23.3 and to file Exhibit 23.3. Exhibit 23.3 is the consent of UHY LLP related to the financial statements of Healthy Offers, Inc. as of December 31, 2022 and 2021 and for the years then ended (the “Auditor’s Consent”). The Auditor’s Consent was inadvertently omitted from the Original Filing. This filing is being made solely to update the exhibit index and provide the Auditor’s Consent and does not update, amend, or modify any other information, statement or disclosure contained in or filed with the Original Filing.

 

 

PART II

 

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 8. Exhibits.

 

The following exhibits are filed as part of this Registration Statement or, where so indicated have been previously filed and are incorporated herein by reference.

 

Exhibit		Description of Exhibit
4.1		Articles of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Registration Statement on Form S-1, as filed with the Commission on November 12, 2008).
4.2		Certificate of Correction of the Registrant, dated April 30, 2018 (incorporated by reference to Exhibit 3.5 of the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, as filed with the Commission on March 12, 2019).
4.3		Third Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.3 of the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Commission on March 10, 2023).
4.4		OptimizeRx Corporation 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K, as filed with the Commission on August 25, 2021).
4.5		Amendment No. 1 to the OptimizeRx 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K, as filed with the Commission on June 7, 2024).
5.1*		Opinion of The Doney Law Firm.
23.1*		Consent of UHY LLP.
23.2*		Consent of The Doney Law Firm (included in Exhibit 5.1).
23.3		Consent of UHY LLP, independent registered public accounting firm for Healthy Offers, Inc.
24.1*		Power of Attorney (included on the signature page to the Original Filing).
107.1*		Filing Fee table.

 

*

Previously filed with Original Filing.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of Massachusetts on July 23, 2024.

 

	OptimizeRx Corporation
	By:	/s/ William J. Febbo
	Name:	William J. Febbo
	Title:	Chief Executive Officer

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities held on the dates indicated.

 

Signature		Title		Date
/s/ William J. Febbo		Chief Executive Officer and Director		July 23, 2024
William J. Febbo		(Principal Executive Officer)
/s/ Edward Stelmakh		Chief Financial Officer and Chief Operations Officer		July 23, 2024
Edward Stelmakh		(Principal Financial and Accounting Officer)
*		Director, Chairperson		July 23, 2024
Lynn O’Connor Vos
*		Director		July 23, 2024
James Lang
*		Director		July 23, 2024
Patrick Spangler
*		Director		July 23, 2024
Gregory D. Wasson
*		Director		July 23, 2024
Catherine M. Klema

 

*By:	/s/ William J. Febbo
	William J. Febbo
	Attorney-in-Fact

 

 

 

II-2

 

Exhibit 23.3

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the incorporation by reference in this Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 (File No. 333-280300) of OptimizeRx Corporation (the “Company”) of our report dated December 29, 2023, with respect to our audit of the financial statements of Healthy Offers, Inc. as of December 31, 2022 and 2021, and for the years then ended, appearing in the Company’s Form 8-K/A filed on January 5, 2024.

 

/s/ UHY LLP

 

Sterling Heights, Michigan

July 23, 2024